Related Experiment Videos

ABCA1 as a New Therapeutic Target for Treating Cardiovascular Disease

John F. Oram

    Drug News & Perspectives
    |April 5, 2003
    PubMed

    Insights

    Targeting the ABCA1 transporter offers a new strategy for cardiovascular disease. Activating ABCA1 drugs can mobilize cholesterol from macrophages, potentially preventing and reversing atherosclerosis.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Cardiovascular Medicine

    Background:

    • Atherosclerotic cardiovascular disease is a leading cause of death.
    • Cholesterol is a key risk factor, but lowering it has limited success.
    • New therapeutic targets are needed for cardiovascular disease.

    Purpose of the Study:

    • To explore the role of the ABCA1 transporter in cholesterol metabolism and cardiovascular disease.
    • To investigate ABCA1 as a potential therapeutic target for atherosclerosis.

    Main Methods:

    • The study focuses on the function of the ATP binding cassette transporter ABCA1.
    • ABCA1's role in cholesterol secretion from macrophages into HDL pathway is examined.
    • Genetic mutations in ABCA1 (Tangier disease) and their link to atherosclerosis are discussed.

    Main Results:

    • ABCA1 is crucial for cholesterol efflux from macrophages.
    • ABCA1 mutations lead to cholesterol accumulation and atherosclerosis.
    • ABCA1-activating drugs show potential for cholesterol mobilization.

    Conclusions:

    • ABCA1 is a promising therapeutic target for cardiovascular disease.
    • Drugs targeting ABCA1 could prevent and reverse atherosclerosis by mobilizing macrophage cholesterol.

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    ABC Transporters: Exporter01:31

    ABC Transporters: Exporter

    ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    ABC Transporters: Importer01:27

    ABC Transporters: Importer

    ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
    In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include: